Contact Us
INNOGLY INNOGLY INNOGLY INNOGLY
Navigation
  • About us
    • COST Action
    • Network members
    • Scientific Outputs
      • Scientific Publications
      • Abstracts from Events
  • News
  • Events
  • Working Groups
    • Development and Cancer
    • Autophagy
    • Immunity
    • GAGs
  • STSM
    • STSM information
    • STSM proposal
    • STSM evaluation
    • Awarded STSMs
  • ITC Grants
  • Training Schools

Logged out

Lost Password?

News

INNOGLY Working Groups Reports 24-54 Months
The reports summarize the activities of the four working groups ...
Read More
INNOGLY WG2: THE GLYCOBIOLOGY OF CELL METABOLIC PROCESSES AT THE NANOSCALE IN HUMAN PATHOLOGY
Dear students, don’t miss this unique opportunity to join the ...
Read More
Young Researchers on stage: International Meeting of Young Researchers – INNOGLY & GLYCONanoPROBES Iasi – Romania, 20th-21st April 2023
The COST Actions 18103 INNOGLY and 18132 GLYCONanoPROBES have joined efforts to organize ...
Read More
Glycans and Glycosciences
an intro for everyone
Read More
Glycosaminoglycans: What Remains To Be Deciphered?
The article "Glycosaminoglycans: What remains to be deciphered?" by Serge ...
Read More

Emerging glyco‐based strategies to steer immune responses

Abstract

Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell‐cell communications and in the regulation of immune responses. Through the interaction with glycan‐binding receptors glycans are able to affect the activation status of antigen presenting cells, leading to either induction of pro‐inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco‐chemists and glyco‐immunologists to develop glycan‐based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review we highlight emerging advances in this field, and in particular we discuss on how glycan‐modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen presenting cells, like dendritic cells. In addition, we address how glycan‐based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan‐based therapies, including chimeric antigen receptor (CAR)‐T cells to achieve targeting of tumor‐associated glycan‐specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity.

https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15830

March 25, 2021

Events

INNOGLY WG2: THE GLYCOBIOLOGY OF CELL METABOLIC PROCESSES AT THE NANOSCALE IN HUMAN PATHOLOGY
Dear students, don’t miss this unique opportunity to join the ...
Read More
Young Researchers on stage: International Meeting of Young Researchers – INNOGLY & GLYCONanoPROBES Iasi – Romania, 20th-21st April 2023
The COST Actions 18103 INNOGLY and 18132 GLYCONanoPROBES have joined efforts to organize ...
Read More
Structural Glycobiology Summer School in Grenoble
Applications are open for Structural Glycoscience Summer School in Grenoble. Free ...
Read More

Follow us on Twitter


Follow INNOGLY

Twitter Timeline

Error: Please set your Twitter oAuth API Keys on Control Panel > Global Settings > API Keys page. (Twitter said: Could not authenticate you.)

COST Action CA18103

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.

https://www.cost.eu/

© Copyright 2025. All Rights Reserved | Powered by innogly.eu | Designed by AWA
  • Imprint
  • /
  • Privacy policy
  • /